Search Results

A Multicenter, Open-label, Phase 3 Study to Evaluate the Long-term Safety and Efficacy in Participants who are Currently on Treatment or in Follow-up in Studies That Include Pembrolizumab (MK3475-587) Brief Summary: The purpose of this study is to evaluate the long-term safety and efficacy of pembrolizumab (MK-3475) in participants from previous Merck pembrolizumab-based parent studies who…

Nadia Ashai, MD, is a fellowship-trained, board-certified medical oncologist and hematologist at Maryland Oncology Hematology. She earned her medical degree from the University of Maryland School of Medicine, followed by residency training at the University of Maryland Medical Center. She then completed a fellowship in oncology at the Albert Einstein College of Medicine, Montefiore Medical…

A phase 3 open-label, randomized, controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator’s choice monotherapy treatment in previously treated patients with incurable, metastatic/recurrent head and neck squamous cell carcinoma (MCLA-158-CL02) MOA: Petosemtamab is a bispecific antibody targeting EGFR and LGR5 Key Eligibility Criteria: Metastatic or locally advanced HNSCC not amenable…

A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours  MOA: Zongertinib is an EGFR wild-type sparing, selective HER2 inhibitor with potent inhibitory activity on all oncogenic HER2 mutations. Key Eligibility Criteria: Subjects with a previously treated,…

Randomized Phase 2b Study of ZEN003694 in Combination with Enzalutamide versus Enzalutamide Monotherapy in Patients with Metastatic Castration-Resistant Prostate Cancer (ZEN003694-201) MOA: ZEN003694 epigenetically regulates gene expression through bromodomain and extra-terminal domain (BET) inhibition. Key Eligibility Criteria: Metastatic, castration-resistant, histologically confirmed prostate cancer that has progressed on prior abiraterone treatment Patient must meet definition of…